Publications

April 2008
Case

Ophthalmic Consultants of Boston and Dr. Bradford J. Shingleton (2004)

By: H. Kent Bowen and Marcelo Pancotto

Dr. Bradford Shingleton has developed some of the highest quality eye surgery techniques in the industry. He involves his nurses and technicians in creating a surgical service that is constantly improving. The case has many details about how Dr. Shingleton works with... View Details

Keywords: Health Care and Treatment; Independent Innovation and Invention; Service Operations; Performance Productivity; Practice; Problems and Challenges; Health Industry; Boston

26 Mar 2024
Research & Ideas

How Humans Outshine AI in Adapting to Change

AI is more likely to struggle in situations where environments shift enough to require a pivot of the self. “In any sort of changing environment setting—like shifting between different workflows, providing personalized care to a wide... View Details

Keywords: by Rachel Layne; Technology; Information Technology

February 2025
Case

Abiomed: A Change of Heart

By: Satish Tadikonda, Faith Robertson and William Marks

After acquiring Impella CardioSystems AG in May 2005, Abiomed Inc., a company focused on cardiac care, ran into a dilemma. Its Impella 2.5 device was approved for use in the European Union, but CEO Michael Minogue had seemingly bet the company's future on the ability... View Details

Keywords: Mergers and Acquisitions; Governing Rules, Regulations, and Reforms; Health Care and Treatment; Business and Government Relations; Medical Devices and Supplies Industry; European Union; United States

Web

Publications - Institute For Strategy And Competitiveness

Feeley, M.D.f, Neema Navai, M.D. Objectives: Patients undergoing radical cystectomy represent a particularly resource-intensive patient population. Time-driven activity based costing (TDABC) assigns time to... View Details

May 2025
Teaching Note

The VideaHealth AI Factory: CEO Florian Hillen on Speed, Scale, and Innovation

By: Tsedal Neeley

Teaching Note for HBS Case No. 425-720. Florian Hillen, co-founder and CEO of VideaHealth, a startup using artificial intelligence (AI) to detect dental conditions on x-rays, spent the early years of his company laying the groundwork for an AI factory. This AI factory,... View Details

Keywords: Diagnostics; Organization Design; Change Management; Disruption; Transformation; Health Care and Treatment; AI and Machine Learning; Technological Innovation; Technology Adoption; Management Style; Organizational Culture; Success; Technology Industry; Health Industry; United States

Research Summary

Health-care Applications

Active postmarketing drug surveillance. There is substantial interest within the U.S. health community and among health policymakers in developing a surveillance system that scans public health databases in order to proactively detect potential drug safety... View Details

January 2025
Supplement

The VideaHealth AI Factory: CEO Florian Hillen on Speed, Scale, and Innovation (B)

By: Tsedal Neeley, Levi Stroud, Ruth Page and Dave Habeeb

Pre-abstract: This multimedia case should be assigned to students in advance of class. Instructors should consider the timing of making the (B) Case videos available to students, as they may reveal key case details.

Abstract: Florian Hillen, co-founder... View Details

Keywords: Diagnostics; Organization Design; Change Management; Disruption; Transformation; Health Care and Treatment; AI and Machine Learning; Technology Adoption; Technological Innovation; Management Style; Organizational Culture; Success; Technology Industry; Health Industry; United States

January 2025
Case

The VideaHealth AI Factory: CEO Florian Hillen on Speed, Scale, and Innovation (A)

By: Tsedal Neeley, Levi Stroud, Ruth Page and Dave Habeeb

Pre-abstract: This multimedia case should be assigned to students in advance of class. Instructors should consider the timing of making the (B) Case videos available to students, as they may reveal key case details.

Abstract: Florian Hillen, co-founder... View Details

Keywords: Diagnostics; Organization Design; Change Management; Disruption; Transformation; Health Care and Treatment; AI and Machine Learning; Technology Adoption; Technological Innovation; Management Style; Organizational Culture; Success; Technology Industry; Health Industry; United States

03 Aug 2010
First Look

First Look: August 3

employees are more likely to speak up and offer solutions when organizations launch information campaigns to promote process improvement and when managers engage in process-improvement activities themselves. We test our hypotheses in the health View Details

Keywords: Martha Lagace

Article

Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users

By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt

Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling... View Details

Keywords: Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States

14 Mar 2017
First Look

First Look at New Research, March 14

highlighting inconsistencies in the care of RA patients in England. In particular, the company considered the current use of biologic medications to treat RA in England as well as how the introduction of... View Details

Keywords: Sean Silverthorne

May 2021
Case

Inclusive Innovation at Mass General Brigham

By: Katherine Baldiga Coffman and Olivia Hull

Massachusetts General Brigham (MGB) Chief Innovation Officer Christopher Coburn had overseen a period of exciting transformation and growth in healthcare innovation at MGB. In November 2019, the health system was the largest recipient of National Institutes of Health... View Details

April 2017
Supplement

Imprimis (C)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel

This case is a supplement to Imprimis (A & B). Set in 2015, it first describes Imprimis’s decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the... View Details

Keywords: Health Care and Treatment; Cost; Moral Sensibility; Competitive Strategy; Decision Choices and Conditions; Pharmaceutical Industry; United States

Web

Biography - Institute For Strategy And Competitiveness

devoted considerable attention to the economics of health care, with a focus on building the intellectual framework for realigning the delivery of health care to maximize value to patients (patient health... View Details

October 2009 (Revised August 2014)
Case

Tengion: Bringing Regenerative Medicine to Life

By: Elie Ofek and Polly Ross Ribatt

Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late... View Details

Keywords: Decision Choices and Conditions; Financial Crisis; Entrepreneurship; Health Care and Treatment; Technological Innovation; Product Launch; Product Development; Research and Development; Biotechnology Industry; United States

07 May 2009
Working Paper Summaries

Broadening Focus: Spillovers and the Benefits of Specialization in the Hospital Industry

Keywords: by Jonathan R. Clark & Robert S. Huckman; Health

02 Mar 2007
What Do You Think?

What Is the Government’s Role in US Health Care?

argued that "Containing costs will come at the expense of something technological advances, profit, access to certain services, and patient choice are likely candidates ." One line of thinking would make both talent and drugs more... View Details

Keywords: by Jim Heskett; Health

August 2024
Article

How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?

By: Leemore S. Dafny, Kate Ho and Edward Kong

Drug copayment coupons to reduce patient cost-sharing have become nearly ubiquitous for high-priced brand-name prescription drugs. Medicare bans such coupons on the grounds that they are kickbacks that induce utilization, but they are commonly used by... View Details

Keywords: Prescription Drugs; Coupons; Impact; Health Care and Treatment; Markets; Price; Spending; Pharmaceutical Industry; United States